Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr Kopetz on the Background of the KRYSTAL-1 Trial in KRAS G12C+ mCRC

April 26th 2024

Scott Kopetz, MD, PhD, FACP, discusses using adagrasib plus cetuximab in patients with metastatic colorectal cancer harboring KRAS G12C mutations.

Fruquintinib Receives Positive CHMP Opinion for Previously Treated mCRC

April 26th 2024

CHMP has voiced its support for the approval of fruquintinib in previously treated metastatic colorectal cancer.

Next-Generation ColoAlert Screening Test Shows High Sensitivity, Specificity for CRC and Adenoma Detection

April 25th 2024

Topline findings with the next-generation ColoAlert® test demonstrated 92% sensitivity and 90% specificity rates for colorectal cancer detection.

Retrospective Data Show Association Between HER2 Expression and Survival Outcomes in mCRC

April 25th 2024

HER2 gene expression is associated with prognostic and predictive value in patients with metastatic colorectal cancer.

HER2 Expression May Hold the Key to Predicting Survival Outcomes in CRC

April 24th 2024

Heinz-Josef Lenz, MD, FACP, discusses the prognostic and predictive value of HER2 expression levels in select patients with colorectal cancer.

Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer

April 23rd 2024

The panel reviews recent data on MRD testing in colorectal cancer, highlighting the INTERCEPT and COSMOS-CRC-01 studies.

Patient Profile 2: A 35-Year-Old Man With Oligometastatic Colorectal Cancer

April 23rd 2024

Benjamin A. Weinberg, MD, presents the case of a 35-year-old man with oligometastatic disease, and the panel provides insights on treatment decisions.

Dr Lenz on the Prognostic Value of HER2 Expression in mCRC

April 19th 2024

Heinz-Josef Lenz, MD, FACP, discusses the prognostic value of HER2 expression in patients with KRAS wild-type metastatic colorectal cancer.

Revisit Every OncLive On Air Episode from March 2024

April 19th 2024

In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.

Dr Kopetz on Adagrasib Plus Cetuximab in KRAS G12C+ mCRC

April 19th 2024

Scott Kopetz, MD, PhD, FACP, discusses the clinical efficacy and safety of adagrasib plus cetuximab in patients with KRAS G12C-mutated mCRC.

Early Data With Copanlisib/Nivolumab Combo Support Further Exploration in MSS CRC

April 18th 2024

Eric S. Christenson, MD, discusses the potential benefit of copanlisib plus nivolumab in PIK3CA-mutant microsatellite stable colorectal cancer.

Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma

April 18th 2024

Michael Leung, PharmD, presents the case of a 57-year-old man with cecal colon adenocarcinoma and provides his initial thoughts, particularly on adverse event management.

Treatment Considerations With Regorafenib in Colorectal Cancer

April 18th 2024

Focusing on the treatment of patients receiving regorafenib, the panel details the management of common adverse events, prophylaxis strategies, and the roles of members within a multidisciplinary team.

Myths Surrounding Liquid Biopsy and ctDNA Testing for MRD

April 15th 2024

Pashtoon Murtaza Kasi, MD, MS, emphasizes key aspects of liquid biopsy and ctDNA testing in the MRD treatment landscape.

BESPOKE CRC: Study of ctDNA-Guided Therapy in Colorectal Cancer

April 15th 2024

Pashtoon Murtaza Kasi, MD, MS, reviews data from the BESPOKE CRC study, highlighting overall results and patient-reported outcomes.

Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC

April 12th 2024

Updated phase 1 findings with botensilimab/balstilimab in MSS/pMMR mCRC show that the regimen elicited respective 12- and 18-month OS rates of 71% and 62%.

Dr Kasi on the Use of ctDNA to Help Inform Adjuvant Treatment Decisions in CRC

April 12th 2024

Pashtoon Murtaza Kasi, MD, M.S on the potential of ctDNA to guide further adjuvant treatment decisions in CRC and other tumor types.

Dr Nassar on MMR Determination by IHC and NGS in CRC and Endometrial Cancer

April 11th 2024

Amin Nassar, MD, discusses the investigation of NGS plus standard IHC to detect dMMR status in patients with colorectal cancer or endometrial cancer.

Dr Park on the Initial Efficacy of Epacadostat Plus Preoperative Chemoradiation in Rectal Cancer

April 11th 2024

Haeseong Park, MD, MPH, discusses phase 1 results of epacadostat plus preoperative chemoradiation in locally advanced rectal cancer.

Insider Insights: Unveiling Takeaways from AACR 2024

April 11th 2024

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.